CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, today announced that Leslie Williams, Chief Executive Officer, will present a corporate overview at the Cowen & Company 39th Annual Healthcare Conference, taking place March 11-13 in Boston, Massachusetts.
| Cowen 39th Annual Health Care Conference | |
| Date: | Monday, March 11 |
| Time: | 3:00pm Eastern Time |
| Webcast: | http://wsw.com/webcast/cowen52/imst |
About ImmusanT, Inc.
At ImmusanT, we are developing a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Our Epitope-Specific Immuno-Therapy™ (ESIT™) platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. Our lead program, Nexvax2®, is in clinical development with the goal of protecting celiac disease patients against the debilitating effects of gluten. www.ImmusanT.com
Media Contact:
Andrew Mielach
Account Supervisor
LifeSci Public Relations
(646) 876-5868
amielach@lifescipublicrelations.com